全球新冠肺炎治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計冠狀病毒治療市場將從 2025 年的 277.1 億美元成長到 2034 年的 135.3 億美元，2026 年至 2034 年的複合年成長率為 -7.66%。

全球新冠感染疾病促使世界各地的醫療系統將重點放在研發有效的治療方法和醫療干預措施上，推動了全球新冠治療市場的快速擴張。各國政府、製藥公司和研究機構已在抗病毒藥物、單株抗體和輔助療法方面投入巨資，以降低疾病的嚴重程度和死亡率。研發投入和緊急醫療支出的激增顯著提高了醫院和醫療機構對新冠治療方案的需求。

推動市場成長的主要因素之一是對新冠病毒及相關病毒感染疾病有效治療方法的持續需求。新變種的出現不斷推高了對抗病毒藥物、免疫療法和先進診斷監測的需求。製藥公司和研究機構之間加強的全球合作也加速了藥物研發和核准流程。

預計新冠病毒治療市場將朝著長期管理策略與疫情應對方向發展。抗病毒藥物和免疫療法的持續研究將改善治療效果。此外，各國政府和衛生機構正在加強醫療基礎設施建設，以更好地應對未來的感染疾病疫情，這將支撐市場的持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球新冠肺炎治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 皮質類固醇
• 抗病毒藥物
• 單株抗體
• 激酶抑制劑
• 其他（抗發炎藥、康復血漿等）

第5章：全球新冠肺炎治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外

第6章：全球新冠肺炎治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球新冠肺炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Eli Lilly And Company
  • Pfizer Inc
  • Merck & Co Inc
  • GSK Plc
  • Celltrion Healthcare Co. Ltd
  • SorrentTherapeutics Inc
  • AstraZeneca

The Coronavirus Treatment Market size is expected to reach USD 13.53 Billion in 2034 from USD 27.71 Billion (2025) growing at a CAGR of -7.66% during 2026-2034.

The global coronavirus treatment market experienced rapid expansion following the outbreak of COVID-19, as healthcare systems worldwide focused on developing effective therapies and medical interventions. Governments, pharmaceutical companies, and research institutions invested heavily in antiviral drugs, monoclonal antibodies, and supportive therapies to reduce disease severity and mortality. This surge in research and emergency healthcare spending significantly boosted the demand for coronavirus treatment solutions across hospitals and healthcare facilities.

One of the main drivers of the market is the continued need for effective treatments for COVID-19 and related viral infections. The emergence of new variants has maintained demand for antiviral medications, immune-based therapies, and advanced diagnostic monitoring. Increased global collaboration among pharmaceutical companies and research institutions has also accelerated drug development and approval processes.

Looking ahead, the coronavirus treatment market is expected to evolve toward long-term management strategies and pandemic preparedness. Continued research into antiviral drugs and immune therapies will likely improve treatment outcomes. Governments and healthcare organizations are also strengthening healthcare infrastructure to better respond to future infectious disease outbreaks, supporting sustained growth in this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Corticosteroids
• Anti-viral
• Monoclonal Antibodies
• Kinase Inhibitors
• Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Gilead Sciences Inc, Eli Lilly and Company, Pfizer Inc, Merck Co Inc, GSK plc, Celltrion Healthcare Co Ltd, SorrentTherapeutics Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CORONAVIRUS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Anti-viral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Kinase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CORONAVIRUS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CORONAVIRUS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CORONAVIRUS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CORONAVIRUS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Gilead Sciences Inc
  • 9.2.3 Eli Lilly And Company
  • 9.2.4 Pfizer Inc
  • 9.2.5 Merck & Co Inc
  • 9.2.6 GSK Plc
  • 9.2.7 Celltrion Healthcare Co. Ltd
  • 9.2.8 SorrentTherapeutics Inc
  • 9.2.9 AstraZeneca